A lthough acoustics as a field of study dates as far back as ancient Greece, it only became an applied science in the 19th century. 33 In 1880, brothers Pierre and Jacques Curie described the ability of sound waves in the form of pressure waves to generate an electrical charge when applied to quartz crystals. 12 They named this phenomenon "piezoelectricity," from the Greek "piezo" for pressure. They also demonstrated the reverse phenomenon: the conversion of electrical charge into sound waves.
They named this phenomenon "piezoelectricity," from the Greek "piezo" for pressure. They also demonstrated the reverse phenomenon: the conversion of electrical charge into sound waves. 12 With the extension of their discoveries to frequencies above the audible human range (> 20 kHz), the field of ultrasonics was born.
In World War I, ultrasound (US) was first put into practical use as sonar in submarines. 3 In the post-World War I period and to this day, the study and application of US in the field of medicine has been divided into 2 tracks: diagnostic and therapeutic. Several innovations, beginning with a fundamental understanding of US and culminating in phase correction and real-time MRI thermometry, have elevated US to a powerful therapeutic tool with the potential for diverse applications.
Physics of Focused Ultrasound
Sound waves are mechanical vibrations that occur through a medium in which molecules oscillate in the direction of wave propagation with frequencies higher than 20 Hz. US waves are typically generated using a piezoelectric (PE) transducer operating at 200 kHz to 4 MHz, depending on the clinical application. 46, 62 PE elements have the unique property of expanding and contracting as a function of the applied voltage, and as they expand and relax, they create US waves in the medium.
PE transducers can be single or multiple, curved or flat in configuration, static or moved mechanically. Transducers can include focusing components, such as radiators, lenses, or reflectors, to enable focal delivery of US waves for tissue ablation. 34, 35, 62 In 1935, Gruetzmacher first designed a curved quartz plate which, as opposed to previous linear plates, could concentrate US beams at a focus, thus creating the first focused US (FUS) transducer. 20 Current systems use phased array transducers with hundreds to thousands of PE elements, which can be used to create multiple focal points to increase the volume of ablation and/or correct for aberrations due to tissue heterogeneities (e.g., bone). 29, 32, 34, 35, 62 Tissue acoustic impedance is a function of substance density and US speed within that substance. As US waves propagate through tissue, they undergo absorption, refraction, and/or reflection, depending on the tissue's impedance properties. These processes, particularly absorption and reflective scatter, result in the exponential attenuation of the US waves. The absorption of acoustic energy translates into temperature elevations in tissue, and, although FUS can disrupt tissue by mechanical forces as well, thermal ablation is the best understood and most significant contributor to the effect of FUS in current applications in neurosurgery. 34, 35, 62 The degree of temperature elevation depends on both tissue characteristics, such as intrinsic ultrasonic and heat transfer properties, and the parameters of sonication, including exposure time and intensity of acoustic energy. In FUS applications, the intensity at the focus of the beam is much higher, enabling significant deposition of ultrasonic energy, leading to focused thermal heating. 33, 35, 46, 66 When tissue is heated to 57°C-60°C or greater, beyond the threshold for protein denaturation, coagulation necrosis occurs. 6, 35, 46 Mechanical forces are not as well understood, but it is believed that US waves cause formation of microbubbles that then oscillate in the presence of continued US waves (i.e., expanding and contracting). 33 This process, known as cavitation, leads to creation of shock waves with high pressures and shear forces causing direct mechanical damage to tissue.
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From the Laboratory to the Clinic:
Development of FUS for Therapeutic Applications
The first report of in vivo testing of FUS in the brain was by Lynn et al. in their 1943 animal experiments conducted at Columbia University. 42 They used a curved FUS transducer (Fig. 1) to sonicate a focus at a 5.5-cm depth from the surface of the scalp. The sonication (835 kHz for 5-15 minutes) caused significant damage to the overlying scalp, skull, and meninges. In their earlier experiments with ex vivo beef liver, they observed that high-intensity FUS (HIFU) with instantaneous ramp-up to maximum intensity was shown to maximize effects at the focus and minimize effects near the source (Fig. 2) . 43 However, this rapid ramp-up resulted in damage to the quartz crystal, and early experiments were limited by a slower increase in signal intensity. Despite the technical limitations at the time, these findings established HIFU as an appropriate methodology for the creation of distinct foci while minimizing trajectory side effects. They also noted that surface and trajectory damage were inversely correlated with focal distance, and inferred that the technology might be more suitable for deep brain targets as opposed to cortical targets. As absorption is proportional to frequency, the authors advised that using a frequency lower than 835 kHz is likely to minimize absorption and heating by superficial tissue and maximize absorption at the focus. 42, 43 Lynn et al. made several other important observations in animals. At a 5.5-cm depth, the focus was in cortical and peripheral subcortical regions. The treated animals displayed neurological dysfunction lasting 2-16 hours, which correlated with the location of sonication. 42 For example, targeting of motor cortex, visual cortex, and cerebellum resulted in transient monoparesis, blindness, and ataxia, respectively. These results implied that FUS could create reversible neuronal lesions. In addition, it was observed that ganglion cells were more sensitive to FUS relative to glia and blood vessels. The minimal damage to blood vessels, when it did occur, was associated with edema and occasional petechial hemorrhage, typically near the tissue interface.
Several years later, William and Francis Fry made the next leap in the field of FUS at the University of Illinois. Given the surface damage seen in the Lynn experiment and concerns about disruption of signal focus, the Fry brothers decided to deliver FUS directly to the dural surface via a craniotomy. Learning from their predecessors, they turned their attention away from cortical and subcortical targets to deep brain targets. In a 1954 paper, Fry's group described their method for targeting deep brain structures using a 4-beam irradiator (Fig. 3 ) that could be moved in relation to a stereotactic apparatus, a concept that was already established for use in lesioning procedures for deep brain targets. 19 This work was the first to demonstrate effective use of stereotaxy in conjunction with FUS in an animal model. Effective lesioning of the thalamus and internal capsule in 31 cats was confirmed on histology, with cellular changes to the irradiated targets shown as soon as 2 hours postprocedure (Fig. 4) . In contrast to Lynn's prior work, there was a strong predilection for ultrasonic destruction of nerve fibers over cell bodies; while targeted thalamic cell bodies were histologically unaffected by the lesions in this experiment, axons in the internal capsule were irreversibly damaged in the focal target. 19 Blood vessels and surrounding tissue showed no evidence of damage at the dosages and times used to create the lesion.
Also in 1954, Petter Aron Lindstrom investigated the use of FUS to perform prefrontal lobotomies in an animal model. 39 He later collaborated with Lars Leksell, using Leksell's custom stereotactic frame, to create deep brain lesions. Seeing the challenges posed by the skull, Leksell turned his attention to the use of ionizing radiation as opposed to US, and in later years, his work laid the foundations for the field of radiosurgery.
Meanwhile, the Fry laboratory went on to demonstrate the neurophysiological properties of lesional reversibility that had been described clinically by Lynn et al. Cortical activity generated in response to flashes of light to the retina, measured by electrodes overlying the visual cortex, could be reversibly suppressed with the correct ultrasonic stimulation of the lateral geniculate nucleus. At the end of the ultrasonic irradiation, the primary evoked potential amplitudes were reduced to less than one-third of baseline but returned to prior baseline within 30 minutes after stimulation was complete. The doses used for this study had been demonstrated to cause no histological change to the underlying neural tissue and introduced the novel concept of FUS neuromodulation. 17 Given the success of the multibeam irradiation in creating focused lesions in animals, the Fry laboratory-in conjunction with the neurosurgery department at the University of Iowa-published the first use of multibeam FUS in human neurosurgery, targeting deep brain structures for treatment of tremor and rigidity in Parkinson's disease (PD). 51 In 1960, Meyers and Fry reported on 48 patients treated with ultrasonic therapy, with significant emphasis on treatment of tremor and rigidity associated with PD (Fig. 5) . 18 Their early studies also included forays into treatment of involuntary movement associated with cerebral palsy and pain syndromes. 20 By the second half of the 20th century, the ability to create focal lesions using FUS was established. However, since it required a craniotomy to avoid surface tissue damage and distortion of US beams by the skull, it was more invasive than the other methods of functional neurosurgery practiced at the time, including stereotactic lesioning and, later, deep brain stimulation (DBS). Two challenges-transcranial application and real-time procedural monitoring-remained for this technology to compete with its contemporaries.
The Issue of the Skull
To create a completely transcranial method and obviate the need for a craniotomy, advances in FUS had to overcome 2 major obstacles: localized heating at the skull and inaccurate beam propagation due to surface tissue heterogeneities. Acoustic attenuation is approximately 30-60 times higher in bone than in soft tissue. Noted even by Lynn et al. in their early experiments, the interaction of US waves with the skull causes rapid, localized heating at the skull, limiting the levels of energy that can be safely applied. 46 This problem was ultimately solved by using a hemispheric transducer at lower frequencies with active scalp cooling, in which circulating water prevents heating and improves the transducer-cranial interface. 46 Lower frequencies lead to reduced absorption at the surface, and the hemispheric arrangement distributes localized heating over a large surface area. 46 As an additional confounding factor, beam propagation and focus are significantly distorted by the impedance mismatch between bone and brain, as well as individual variations in skull shape, thickness, and marrow-to-cortical bone ratio. Even into the early 1990s, this problem was insurmountable. The creation of a phased array, in which individual phase offsets correct for the delays and variations in wave propagation encountered throughout the skull, 46 allowed for precise targeting previously only possible when targeting through a craniotomy window. After the development of monitoring technology allowing for accurate acoustic feedback, 59 a hydrophone was used to calculate the phase shifts generated through human skull. 29 While successful phase shifting had been used previously in one-dimensional arrays, the 1998 paper by Hynynen and Jolesz was the first to combine a multidimensional array with a successful phase correction method. 29 Building on this work, the authors went on to demonstrate that phase corrections based on information derived from pretreatment CT scans could enable accurate, patient-specific transcranial FUS treatment. 8, 27 These methods were foundational to the development of modern FUS technology, allowing for the treatment of deep brain structures completely noninvasively. 
Real-Time Monitoring by MR Thermometry
The early adopters of HIFU-mediated thermal ablation were general surgeons who employed this technique in prostate, urological, breast, and gynecological tumors. 25 In these applications, surgeons had a wide soft-tissue window that allowed them to use diagnostic US technology to guide and monitor treatment in real time. In neurosurgical applications, the skull created a major technical obstacle, interfering with ultrasonic visualization of underlying changes to tissue. In the late 1980s to early 1990s, Dr. Ferenc Jolesz's group, working at Brigham and Women's Hospital alongside Drs. Peter Black and Marvin Fried, at the departments of neurosurgery and otorhinolaryngology, respectively, pioneered the development of intraoperative MR image guidance (reviewed by Mislow et al. 53 ). After the opening of the Advanced Multimodality Image Guided Operating (AMIGO) suite at Brigham and Women's Hospital in the mid-1990s, Jolesz and his contemporaries turned their attention to actualizing intraoperative MR thermometry as a tool to guide FUS procedures by monitoring temperature changes generated at the US focus within the brain in real time. [9] [10] [11] By the late 1990s, Jolesz's group showed that low-power sonications could raise the temperature at the target to 40°C-42°C without causing permanent damage. These subthreshold sonications created a heat signature that can be monitored using MR thermometry to help localization and targeting prior to the high-power, ablative sonications. 32 Real-time monitoring of FUS therapy was needed not only to localize the therapeutic focus but also to supervise the tissue changes associated with thermal damage. As mentioned previously, the temperature needed to cause cellular death via thermal coagulation during a short exposure is approximately 55°C-60°C. 48, 66 Not surprisingly, the biological effects caused by temperature elevation generated during the subthreshold sonications do not dissipate instantaneously. Indeed, as early studies on the effects of hyperthermia demonstrated, the extent of tissue damage is related to the overall thermal dose delivered to the target, which is a nonlinear function of the cumulative temperature change and time of sonication. 13, 49 In addition, the energy required by the transducer to generate a goal temperature varies based on patient-specific trajectory characteristics (e.g., skull thickness). In subsequent years, Jolesz and colleagues worked on characterizing thermal dosimetry to a point that eventually allowed for the prediction of lesion size following sequential sonications and for the real-time monitoring of thermal lesioning (Fig. 6) . 7, 47, 48 In 1996, Jolesz and his group first described the in vivo use of MR-guided FUS (MRgFUS) for the ablation of breast fibroadenomas. 28 The first neurosurgical application of MRgFUS followed in the early 2000s, as phased arrays became available to effectively target through the intact skull. In 2010, a collaboration between Jolesz's group at Brigham and Women's Hospital and Dr. Kullervo Hynynen at the University of Toronto, reported the first transcranial application of MRgFUS in 3 patients with recurrent, inoperable glioblastomas or brain metastases (Fig.  7) . 46 While the early version of the transducer used in this study was unable to reach suprathreshold temperatures required for ablation, design and engineering modifications to the transducer have since addressed this limitation, and in 2016, the MRgFUS ExAblate 4000 system (InSightec Inc.) was approved by the FDA for intracranial use in the treatment of essential tremor (ET) based on the clinical trial reported by Elias et al. (Fig. 8) . 15 
Clinical Applications of MRgFUS
Given its suitability for the targeting of deep brain structures, MRgFUS has been investigated as a potential treatment modality for the treatment of ET, PD, obsessivecompulsive disorder, major depressive disorder, neuropathic pain, and epilepsy. More recently, research has also focused on 2 possible applications of MRgFUS in neu- rooncology: direct tumor ablation and facilitation of drug delivery by selective opening of the blood-brain barrier (BBB).
Essential Tremor
Unilateral MRgFUS lesioning of the ventral intermediate nucleus of the thalamus was first reported as a treatment for medically refractory ET in 2013. 14, 40, 68 This work was followed in 2016 by a larger, prospective, shamcontrolled trial of the technique. 15 The experimental group had a mean improvement in tremor score in the treated upper extremity of 47% at 3 months, sustained at 40% improvement at the 1-year posttreatment mark. This was accompanied by significant improvement in function and quality of life. The most common adverse events were paresthesia and gait disturbance occurring at rates of 38% and 36%, and subsequently declining to 14% and 9%, respectively, at the 1-year mark.
Parkinson's Disease
MRgFUS thalamotomy has also been reported for the treatment of medically refractory parkinsonian tremor with significant improvement in tremor of both the upper and lower extremities on the treated side at 6 months posttreatment, although there was a trend toward tremor recurrence. 58, 68 The adverse events profile was similar to that reported in earlier MRgFUS thalamotomy work. Jeanmonod et al. subsequently reported their experience targeting the pallidothalamic tract with sonication parameters used for MRgFUS thalamotomy and found a mean improvement of 57% on the Unified Parkinson's Disease Rating Scale (UPDRS) in a series of 8 patients. 34 After some modifications to the treatment parameters, patients experienced an improvement of 60.9% in the UPDRS, comparable to published outcomes from radiofrequency ablation of this area. 44 Currently MRgFUS is approved for the treatment of parkinsonian tremor and dyskinesia in Europe and Israel, 68 and is currently undergoing several Phase 1 and 2 clinical trials in North America and Korea looking at a range of targets (clinical trial registration nos. NCT02252380, NCT0200324, and NCT02246374).
Neuropsychiatric Conditions
Bilateral capsulotomy using MRgFUS resulted in a significant improvement in depression and anxiety, sustained for at least 6 months, in a series of 4 patients with obsessive-compulsive disorder. 37 This indication is currently undergoing Phase 2 clinical trials in Korea (clinical trial registration no. NCT01986296) and in North America (clinical trial registration no. NCT03156335). Similarly, MRgFUS is also under investigation for the treatment of medication-refractory major depressive disorder (clinical trial registration no. NCT02348411).
Chronic Pain
MRgFUS lesioning of the central lateral thalamic nucleus for chronic neuropathic pain syndromes in a series of 11 patients showed a 49% and 57% pain relief at the 3-month and 1-year follow-up, respectively. 34 Trigeminal neuralgia had originally been avoided due to concerns about heating of surrounding sensitive structures. However, in 2013, a cadaveric study demonstrated that with the implementation of "no-pass" regions of the skull base, the trigeminal ganglion could be lesioned without significantly elevating the temperature of surrounding structures.
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Epilepsy
The application of MRgFUS to the treatment of epilepsy has taken 2 approaches: the suppression of epileptic activity and the lesioning of epileptic foci. Animal experiments have demonstrated that low-intensity, pulsed FUS was able to suppress epileptic activity in the cortex of a rat. 52 A feasibility study of low-intensity FUS pulsation for the suppression of temporal lobe epilepsy is currently underway (clinical trial registration no. NCT02151175). A feasibility study for MRgFUS lesioning for the treatment of subcortical lesional epilepsy is also underway (clinical trial registration no. NCT02804230).
Direct Tumor Ablation
Ultrasonographic ablation of malignancies extends as far back as animal studies in Japan in the 1930s and human studies by the Germans and Swiss in the 1940s. [22] [23] [24] 56 Given the noninvasive nature of the technology, FUS was theorized to have significant potential for the treatment of surgically inaccessible brain tumors. In 1991, Guthkelch et al. described FUS-mediated tumor ablation via craniotomy in 15 patients with primary high-grade gliomas, but the authors noted inconsistent heating throughout the tumor bed. 21 In the early 2000s, once MR guidance of FUS procedures was available, investigators revisited MRgFUS as a tool for tumor ablation, using MRgFUS via a craniotomy to ablate glioblastoma lesions in 3 separate patients. 57 Progression-free survival was 4 and 9 months for 2 of the patients, and the third still had no progression by time of reporting at 39 months after MRgFUS treatment. Notably, 1 of the 3 patients experienced hemiparesis due to the unintended sonication trajectory damage outside the target zone. The first completely transcranial sonication of brain tumors in 3 glioblastoma patients was performed at Brigham and Women's Hospital a few years later. 46 However, power limitations prevented sufficient heating for tumor ablation and thermal necrosis.
Blood-Brain Barrier
As far back as the 1950s, Ballantine et al., working at Massachusetts General Hospital, observed the localized extravascular leakage of trypan blue dye, due to US-mediated BBB disruption, in the absence of damage to surrounding neural tissue after FUS sonication.
1,2 FUSmediated BBB opening occurs via a process of cavitation, as opposed to hyperthermia. Early attempts to harness these effects were complicated by microhemorrhage and damage to neighboring parenchyma. 67 It was later demonstrated that the intravascular injection of preformed microbubbles at the time of sonication helped concentrate the sonication effect to the intraluminal side of the vessel wall. 30, 31, 60 The use of preformed microbubbles meant that a lower-energy sonication could be used to cause BBB opening, reducing effects on surrounding neural tissue and improving the safety profile. 31 Through the use of specific sonication parameters alongside preformed microbubbles, MRgFUS can open the BBB in a safe, spatially selective, and reversible fashion. 31, 50, 67 Preclinical studies have demonstrated the use of FUS to enhance the delivery of a number of chemotherapeutic agents, including biological agents, across the BBB in rats, 41, 63, 64 rabbits, 38 and nonhuman primates. 45 Additional studies have applied this technology to deliver other substances, including stem cells, nucleic acids, and antibodies, for the treatment of neurodegenerative diseases. 4, 5, 36, 38 Although no human trials have been completed as of yet, MRgFUS-mediated BBB opening remains an active area of exploration. 26 
Intracranial Thrombolysis
Prior research has demonstrated that application of US enhances intravascular thrombolysis when administered along with tissue plasminogen activator. 65 FUS for the treatment of ischemic stroke, however, remains in the early preclinical phase, with in vitro and animal models having demonstrated initial feasibility. 16, 61 MRgFUS has also been explored for thrombolysis in intraparenchymal hemorrhage. Results from a cadaveric animal model of intracranial hemorrhage demonstrated that FUS led to sufficient clot liquefaction to allow for needle aspiration of the lysate. 54 
Conclusions
After decades of research across multiple institutions, many of the early technological obstacles to the clinical use of FUS have been resolved, and MRgFUS is now a powerful neurosurgical tool. Applications involving direct lesioning of neural tissue are by far the closest to routine clinical use. Other applications of MRgFUS technology remain in early clinical and preclinical development stages. Nonetheless, considering the promising and potentially exciting indications under investigation, we appear to be poised on the threshold of a golden age for this technology.
